Press Releases Scilex Holding Company

Equities

SCLX

US80880W1062

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-09 EDT			5-day change	1st Jan Change
0.8302 ^USD	-2.00%		-2.15%	-59.30%

04-16	Scilex Issues Preliminary Q1 Sales Results for ZTlido	MT
03-20	Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scilex Holding Company Announces $15 Million Registered Direct Offering	04-24	AQ
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for Gross and Net Sales for ZTlido for the First Quarter 2024	04-17	AQ
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses	04-16	AQ
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group	04-10	AQ
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool	04-09	AQ
Scilex : Submission of Matters to a Vote of Security Holders - Form 8-K	04-05	PU
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend	03-27	AQ
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients	03-21	AQ
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed	03-20	AQ
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®	03-20	AQ
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation	03-19	AQ
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada	03-18	AQ
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.	03-15	AQ
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement	03-15	AQ
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults	03-06	AQ
Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering	03-05	AQ
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024	03-05	AQ
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates	03-04	AQ
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024	03-02	AQ
Scilex Holding Company Announces $10 Million Bought Deal Offering	02-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Scilex Holding Company

Equities

SCLX

US80880W1062

Press Releases

Filters